David Zaccardelli Pharm.D., Acting Chief Executive Officer
David Moore, President and Chief Commercial Officer
Mr. Moore is responsible for commercial development. He has spent over 15 years developing and managing pharmaceutical commercial programs, with the majority of those years spent with the Ortho-McNeil and Janssen Pharmaceutical divisions within Johnson & Johnson. Mr. Moore has held leadership roles in key sales and marketing functions, and was part of teams that developed and executed launch plans for several prescription pharmaceuticals for both primary and acute care settings. He developed payer value platforms for several therapeutic areas including antibiotics, pain and women’s health, in which he successfully implemented pricing and reimbursement strategies with hospitals and managed care organizations. Following Johnson & Johnson, he was chief business officer and vice president of Worldwide Commercial Operations of Tranzyme, Inc., where he was responsible for building the commercial organization as well as in- and out-licensing clinical-stage assets and was chief business officer of Ocera Therapeutics where he was responsible for developing the commercial plans for an Orphan-designated advanced liver disease product for both the community and acute care markets. Mr. Moore received his B.Sc. in Biology from Towson University and an M.B.A. from Lehigh University, and a second graduate degree in Health Policy Excellence from Thomas Jefferson University.
Mark W. Hahn, Executive Vice President and Chief Financial Officer
Mr. Hahn has over 25 years of experience as a senior financial executive in biotechnology and high technology companies. he has conducted over $500 million in financial transactions for both public and private companies. Prior to joining Cempra, Mark was CFO of Athenix Corp., a leading agricultural biotechnology company where he led the company in its $400 million merger with Bayer CropScience. He previously was the CFO of several rapidly growing technology companies including BuildLinks, Inc. and Charles & Colvard, Ltd., where he led the growth of the firm from three to 75 employees and spearheaded that company's IPO. Mark began his career with Ernst & Young. Mr. Hahn holds a Bachelor of Business Administration degree in Accouning and Finance from the University of Wisconsin-Milwaukee and is a Certified Public Accountant in the State of Maryland.
David Oldach, M.D., FIDSA, Chief Medical Officer
David Oldach joined Cempra Pharmaceuticals in 2011. Between 2006 and 2011, Dr. Oldach directed clinical research at Gilead Sciences, Inc., where his drug development experience ranged from IND/first-in-human trial development and execution through NDA-supportive Phase 3 protocol development and execution. Dr. Oldach received his Medical Degree, Magna Cum Laude, from the University of Maryland School of Medicine and completed a residency in Internal Medicine at the Massachusetts General Hospital. He completed an Infectious Disease Fellowship at Johns Hopkins University School of Medicine, serving under John Bartlett. His academic clinical research included studies in community-acquired pneumonia and surgical infections, as well as HCV pathogenesis. At the time of his transition from academic medicine to industry, Dr. Oldach was a tenured Associate Professor of Medicine at the University of Maryland School of Medicine and served as the Infectious Diseases Section Chief in the Baltimore Veterans Administration Hospital.
John Bluth, Executive Vice President, Investor Relations and Corporate Communications
Prior to joining Cempra, Mr. Bluth headed investor relations and corporate communications for two of Silicon Valley’s leading biotechnology companies, CV Therapeutics, which was acquired in 2009, and Aviron, which was acquired in 2002. Before joining Aviron, Mr. Bluth led the west coast healthcare practice for Fleishman-Hillard, an international public relations firm. From 2009-2012, he was senior vice president of investor relations and group communications at German-based Elster Group, one of the world’s largest electricity, gas and water measurement and control providers. Mr. Bluth served as a member of Elster’s group executive board and built the investor relations and corporate communications functions for the company through its initial public offering in 2009. Elster was acquired in 2012. From 2012 through mid-2016, Mr. Bluth was senior vice president of investor relations and corporate communications and served on the executive committee at PowerSecure International, Inc., a leading provider of energy technologies and services to electric utilities and their large industrial, commercial, institutional and municipal customers. PowerSecure was acquired in May 2016. Mr. Bluth holds a Bachelor’s degree in physiology from Cornell University.
Carl T. Foster, Executive Vice President, Business Development
Carl T. Foster is the Executive Vice President, Business Development for Cempra Pharmaceuticals. Prior to joining Cempra, he was CEO of Jurilab, a European-based genomics company. Carl has also held Vice President-level positions with Nanogen, King Pharmaceuticals, Oxford GlycoSciences and Praecis Pharmaceuticals and as General Manager of Intracel BV, a Netherlands-based immunology company. Prior to that he was with Merck, Inc. and Astra Merck where he had increasing levels of responsibilities in sales, marketing, product development, and business development. Mr. Foster has served as an advisor to pharmaceutical and biotechnology companies as a consultant and as a Managing Director with Ferghana Partners, Inc., an international investment banking group in New York. Carl has an MBA in Marketing and MS in Biochemistry from the University of Kansas where he conducted neurochemical research.
Gary Horwith, M.D., Executive Vice President, Quality and Safety
David Pereira, Ph.D., Senior Vice President of Chemistry
Dr. David Pereira has over 20 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Cempra, he was a Director in the Synthesis Group of Cardinal Healthcare, where he was responsible for the process development of numerous drug candidates. He previously held positions at Baxter Healthcare in their IV Systems Division, Hemoglobin Therapeutics Group and the Corporate Research and Technical Division. He worked in parenteral drug development, medical product development and hemoglobin-based oxygen carrying solutions. Dr. Pereira earned his B.S. degree in Biochemistry from Virginia Tech followed by a Ph.D. in Medicinal Chemistry from Virginia Commonwealth University. He continued his training as a post-doctoral fellow at the University of Illinois.